We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?
Read MoreHide Full Article
Tilray, Inc. (TLRY - Free Report) is scheduled to report third-quarter 2020 results on Nov 9, after market close.
In the last reported quarter, the company beat earnings expectations by 3.70%. However, the company has a disappointing track record. Tilray missed earnings estimates in three of the last four quarters, the average negative surprise being 40.61%.
Let us see how things have shaped up prior to this announcement.
Factors at Play
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids.
Revenues increased 10% year over year in the last reported quarter, driven by growth in cannabis sales, improvement in International Medical and contribution from Manitoba Harvest hemp products sales. However, revenues were down sequentially due to declines in Adult Use and Canada Medical as a result of the COVID-19 impact, pantry-loading in March, the temporary closure of stores in Ontario, changes in purchasing behavior by the provinces, the shift to curbside pickup or delivery, and the limited number of retail locations added during the second quarter of 2020. Hence, similar trends have most likely prevailed in the to-be-reported quarter.
Notably, Tilray acquired Manitoba Harvest — a hemp and natural foods producer in Winnipeg, Manitoba — in 2019. The acquisition might have spurred demand year over year for the company’s products in the third quarter.
Gross margin declined in the previous quarter due to introductory shipments made at lower margins in International Medical and a one-time bulk transaction associated with the termination of a supply contract. Nevertheless, the company has undertaken significant steps to drive efficiencies across the business and the positive impact of these actions might be reflected in the upcoming quarterly results.
On the last call, management stated that growth in International Medical revenues will outpace other segments in the coming quarters. However, investors will be keen to know the magnitude of the adverse impact of the coronavirus outbreak on the company’s business as the pandemic gains steam again.Moreover, the company ended the second quarter of 2020 with $137.2 million in cash and cash equivalents. Investors will focus on the company’s plans to manage operations with the available cash resources.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Tilray this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is 0.00%.
Zacks Rank: The company currently carries a Zacks Rank of 4 (Sell).
Share Price Performance
Tilray’s stock has depreciated 61.1% in the year so far compared with the industry’s decline of 11.4%.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Regenxbio, Inc. (RGNX - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #3.
Mylan has an Earnings ESP of +1.69% and a Zacks Rank #3.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?
Tilray, Inc. (TLRY - Free Report) is scheduled to report third-quarter 2020 results on Nov 9, after market close.
In the last reported quarter, the company beat earnings expectations by 3.70%. However, the company has a disappointing track record. Tilray missed earnings estimates in three of the last four quarters, the average negative surprise being 40.61%.
Let us see how things have shaped up prior to this announcement.
Factors at Play
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids.
Revenues increased 10% year over year in the last reported quarter, driven by growth in cannabis sales, improvement in International Medical and contribution from Manitoba Harvest hemp products sales. However, revenues were down sequentially due to declines in Adult Use and Canada Medical as a result of the COVID-19 impact, pantry-loading in March, the temporary closure of stores in Ontario, changes in purchasing behavior by the provinces, the shift to curbside pickup or delivery, and the limited number of retail locations added during the second quarter of 2020. Hence, similar trends have most likely prevailed in the to-be-reported quarter.
Notably, Tilray acquired Manitoba Harvest — a hemp and natural foods producer in Winnipeg, Manitoba — in 2019. The acquisition might have spurred demand year over year for the company’s products in the third quarter.
Gross margin declined in the previous quarter due to introductory shipments made at lower margins in International Medical and a one-time bulk transaction associated with the termination of a supply contract. Nevertheless, the company has undertaken significant steps to drive efficiencies across the business and the positive impact of these actions might be reflected in the upcoming quarterly results.
On the last call, management stated that growth in International Medical revenues will outpace other segments in the coming quarters. However, investors will be keen to know the magnitude of the adverse impact of the coronavirus outbreak on the company’s business as the pandemic gains steam again.Moreover, the company ended the second quarter of 2020 with $137.2 million in cash and cash equivalents. Investors will focus on the company’s plans to manage operations with the available cash resources.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Tilray this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is 0.00%.
Zacks Rank: The company currently carries a Zacks Rank of 4 (Sell).
Share Price Performance
Tilray’s stock has depreciated 61.1% in the year so far compared with the industry’s decline of 11.4%.
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Geron (GERN - Free Report) has an Earnings ESP of +6.25% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regenxbio, Inc. (RGNX - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #3.
Mylan has an Earnings ESP of +1.69% and a Zacks Rank #3.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>